+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases



T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases



Journal of Experimental Medicine 154(4): 1033-1042



Progressive growth of the P815 mastocytoma in semisyngeneic mice evokes the generation of a T cell-mediated mechanism of immunosuppression that inhibits the capacity of passively transferred, tumor-sensitized T cells from regressing this tumor in recipient mice. This conclusion is based on two findings: (a) that it is possible to demonstrate adoptive T cell-mediated regression of established tumors, but only if the tumors are growing in T cell-deficient recipients, and (b) that adoptive T cell-mediated regression of tumors in these recipients can be inhibited by the infusion of splenic T cells from T cell-intact, tumor-bearing donors. The results of additional experiments designed to measure the effect of decreasing the number of suppressor cells and the time that they are infused, relative immune cells, indicate that the function of suppressor cells in this model is to inhibit the replication of passively transferred immune T cells. The results obtained with the P815 mastocytoma are similar to those obtained previously with a chemically induced fibrosarcoma. They show, in addition, that passively transferred immune cells are capable of destroying already seeded metastases in T cell-deficient recipients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 044513244

Download citation: RISBibTeXText

PMID: 6457075

DOI: 10.1084/jem.154.4.1033


Related references

Development of primary in vitro tumor-specific CTL to the P815 mastocytoma A potential strategy for adoptive immunotherapy. FASEB Journal 8(4-5): A208, 1994

Application of Candida solubilized cell wall beta-glucan in antitumor immunotherapy against P815 mastocytoma in mice. International Immunopharmacology 2(1): 59-67, 2002

Antibody-mediated enhancement of infection by dengue virus of the P815 murine mastocytoma cell line. Biken Journal 29(2): 51-55, 1986

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. Journal of Experimental Medicine 157(3): 1040-1052, 1983

Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: Comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models. Experimental Hematology 27(3): 461-469, 1999

Mast cell granules inhibit macrophage-mediated lysis of mastocytoma cells (P815) and nitric oxide production. Journal of Leukocyte Biology 53(4): 446-453, 1993

Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes. Anticancer Research 17(2a): 1083-1088, 1997

Synergic action of lipopolysaccharide and muramyl dipeptide in immunotherapy of DBA/2 mice with mastocytoma P815. Bulletin of Experimental Biology and Medicine 108(6): 1782-1785, 1989

The synergistic action of lipopolysaccharide and muramyl dipeptide in the immunotherapy of DBA/2 mice with mastocytoma P815. Biulleten' Eksperimental'noi Biologii i Meditsiny 108(12): 721-724, 1989

Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens. Anticancer Research 17(5a): 3653-3658, 1997

Synergistic action of lipopolysaccharide and muramyl dipeptide on the immunotherapy of dba 2 mice bearing mastocytoma p815. Byulleten' Eksperimental'noi Biologii i Meditsiny 108(12): 721-724, 1989

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Ii. T lymphocyte-mediated cytolysis. Journal of Experimental Medicine 152(5): 1184-1193, 1980

Inhibition of metabolism-mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma (line P815) cells. Biochemical Pharmacology 31(18): 2921-2928, 1982

Genistein-induced apoptosis of p815 mastocytoma cells is mediated by Bax and augmented by a proteasome inhibitor, lactacystin. Nutrition and Cancer 42(2): 248-255, 2002

Inhibition of metabolism--mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma cells (line P815). Advances in Experimental Medicine and Biology 136 Pt B: 1067-1075, 1981